Angiotech Pharmaceuticals, Inc. (Angiotech) announced that it has received approval to begin marketing the Quill SRS Polydioxanone (PDO), MONODERM, Polypropylene and Nylon product lines in Brazil. The Quill SRS product lines include two absorbable sutures MONODERM and PDO, and two nonabsorbable sutures Polypropylene and Nylon, and are approved for sale in the US, Europe, and Canada.

Quill Self-Retaining System (SRS) represents a technology in wound closure made possible by bidirectional fixation within the wound. Its patented design allows the surgeon to begin closure at the midpoint of the wound and suture in two directions from the midpoint. Barbs within the Quill SRS distribute tension across the wound and eliminate the need for knots.